BCBilin Cetinkaya

Bilin Cetinkaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bilin Cetinkaya has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictive factors of early reactivation after ıntravitreal ranibizumab in agressive retinopathy of prematurity

    by N. Sahinoglu-Keskek, I. Akkoyun, B. Torer, B. Cetinkaya, H. Gülcan, G. Yilmaz, S. Oto


  • Open Access

    Differential Diagnosis And Management In Neonatal Mass Lesions: Ten Years Experience

    by Elif Habibe Aktekin, Ayşe Erbay, Semire Serin Ezer, Bilin Çetinkaya, Şenay Demir Kekeç, Bermal Hasbay, Nalan Yazıcı

    Introduction: Neonatal tumors are rare and there is no standard approach to these diseases. Besides, cancer is an important cause of perinatal morbidity and mortality. The aim of this study is to analyze the incidence, clinical features and management of these exceptional tumors which were followed up at our center. Material and Method: We assessed all babies with solid masses admitted to our hospital between 2007-2018 retrospectively. The age, sex distribution, birth weight and gestational age, type of lesion, management and outcome were studied. Results: Of total; there were 62 cases over 10 years in which the most common solid neonatal tumor was germ cell tumor (30.6%). Forty two lesions were located in the abdomen. The majority of cases (48.3%) underwent only surgery for treatment strategy. Conclusion: In spite of limited management experience for newborn tumors, thanks to renovations in prenatal diagnostic methods and sufficient perinatal care, survival can be improved in specialised multidisciplinary centers.

  • Open Access

    İdiyopatik konjenital tek taraflı vokal kord paralizisi: yenidoğanda tekrarlayan pnömoni ataklarının nadir bir nedeni

    by Hande Gülcan, Bilin Çeti̇nkaya, Birgin Törer, Fulya Özer

  • Effects of Iron(II) Salts and Iron(III) Complexes on Trace Element Status in Children with Iron-Deficiency Anemia

    by Eser Yildirim Sözmen, Kaan Kavakli, Bilin Cetinkaya, Yasemin Delen Akçay, Deniz Yilmaz, Yesim Aydinok

    Iron-deficiency anemia (IDA) is the most common nutritional deficiency in childhood throughout the world. Although it has been shown that IRA is associated with elevated plasma copper and depleted zinc levels in children, there are conflicting results on the effect of iron supplementation on the absorption of these elements. The aim of this study was to investigate the effects of ferrous and ferric iron supplementation on the trace element status in children (n=25, aged 8–168 mo) with IDA. Fourteen of them were treated with ferric hydroxide-polymaltose complex (Ferrum, Vifor, Switzerland) (6 mg/d in the first 3 mo for initial therapy and 3 mg/kg for 3 mo as maintenance); the others were treated with a ferrous sulfate complex (FerroSanol, Schwarz, Germany) (6 mg/d in the first 3 mo for initial therapy and 3 mg/kg for 3 mo as maintenance). Plasma copper, zinc, and ceruloplasmin levels as well as hematological parameters were determined at baseline and the first, third, and sixth month of the treatment period. The hemoglobin and iron levels of patients in both groups were higher in the first and sixth months compared to baseline. Although the ceruloplasmin levels were depleted (48.9 mg/dL vs 41.4 mg/dL, p=0.035) during ferrous iron treatment, the copper and zinc levels remained unchanged. On the other hand, ferric iron supplementation led to an increase in zinc levels in the sixth month of treatment (0.77 mg/L vs 1.0 mg/L, p=0.021). The plasma copper levels were lower in the ferrous iron-treated group at the end of the first month of treatment than in the ferric irontreated group (1.06 mg/L vs 1.29 mg/L, p=0.008). In conclusion, our data showed that copper and ceruloplasmin metabolisms were affected by ferrous iron supplementation, whereas ferric iron kept them to normal levels of zinc, possibly by affecting their absorption. We conclude that the copper and zinc status of patients with IDA should be taken into consideration before and after iron therapy.